ストックスクリーナーアプリを入手
11.00
0.00%
0.00
アフターアワーズ：
11.00
前日終値:
$11.00
開ける：
$11.34
24時間の取引高:
105.00K
Relative Volume:
3.42
時価総額：
$22.83M
収益：
-
当期純損益:
$-4.85M
株価収益率:
-35.48
EPS:
-0.31
ネットキャッシュフロー:
$-3.95M
1週間 パフォーマンス:
+8.06%
1か月 パフォーマンス:
-10.13%
6か月 パフォーマンス:
-26.62%
1年 パフォーマンス:
-5.17%
1日の値動き範囲:
$10.83
$11.44
1週間の範囲:
$9.55
$12.00
52週間の値動き範囲:
$8.12
$22.90
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
CVKD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
11.00 | 22.83M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-18 | 開始されました | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc (CVKD) 最新ニュース
Cadrenal Therapeutics acquires VLX-1005 from Veralox - MSN
Cadrenal's Quiet Expansion Play Is Starting to Get Loud - The Joplin Globe
Cadrenal Therapeutics (NASDAQ: CVKD) adds HIT, Factor XIa drugs in quiet expansion - Stock Titan
Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market - ACCESS Newswire
Cadrenal Therapeutics (NASDAQ: CVKD) builds multi-asset anticoagulation platform in $40B market - Stock Titan
Cadrenal Therapeutics acquires late-stage drug assets from Maryland biotech - The Business Journals
Cadrenal Therapeutics acquires VLX-1005 for heparin-induced thrombocytopenia - TipRanks
Cadrenal Therapeutics Acquires VLX-1005 from Veralox - TipRanks
Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox By Investing.com - Investing.com Canada
Cadrenal Therapeutics acquires VLX-1005, a first-in-class Phase 2 12-LOX inhibitor for patients with heparin-induced thrombocytopenia - marketscreener.com
Cadrenal Therapeutics (Nasdaq: CVKD) adds Phase 2 12-LOX HIT therapy with FDA Fast Track - Stock Titan
Cadrenal Therapeutics (CVKD) Stock Analysis Report | Financials & Insights - Benzinga
Aug Gainers: Can Cadrenal Therapeutics Inc stock deliver strong Q4 earnings2025 Sector Review & Daily Momentum Trading Reports - moha.gov.vn
Is Cadrenal Therapeutics Inc. stock safe for conservative investorsGap Up & Weekly Market Pulse Updates - Newser
Why Cadrenal Therapeutics Inc. stock attracts global investorsGap Up & Fast Entry Momentum Trade Alerts - Newser
The Technical Signals Behind (CVKD) That Institutions Follow - news.stocktradersdaily.com
Can Cadrenal Therapeutics Inc. stock deliver strong Q4 earningsQuarterly Portfolio Summary & Daily Stock Trend Watchlist - Newser
Cadrenal Therapeutics, Inc. (CVKD) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board By Investing.com - Investing.com Australia
Cadrenal Therapeutics appoints Dr. Lee Golden to board of directors - marketscreener.com
Cadrenal Therapeutics Appoints Dr. Golden to Board - TipRanks
Cadrenal Therapeutics Appoints New Director - TradingView
Cadrenal Therapeutics, Inc. Appoints Dr. Lee Scott Golden to Board of Directors - Quiver Quantitative
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board - Investing.com
Cadrenal Therapeutics, Inc. Appoints Lee Scott Golden, M.D. as Independent Director and Member of Science and Technology Committee - marketscreener.com
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors - Sahm
Is Cadrenal Therapeutics Inc. stock affected by interest rate hikes2025 Risk Factors & Real-Time Volume Spike Alerts - BỘ NỘI VỤ
Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis - MarketBeat
Will Cadrenal Therapeutics Inc. stock sustain high P E ratiosWeekly Investment Summary & Smart Allocation Stock Tips - BỘ NỘI VỤ
Precision Trading with Cadrenal Therapeutics Inc. (CVKD) Risk Zones - news.stocktradersdaily.com
Why Cadrenal Therapeutics Inc. stock could see breakout soonJuly 2025 Spike Watch & Growth Focused Stock Reports - newser.com
Institutional scanner results for Cadrenal Therapeutics Inc.2025 Earnings Impact & Step-by-Step Trade Execution Guides - newser.com
Is Cadrenal Therapeutics Inc. stock a good choice for value investors2025 Sector Review & Safe Entry Zone Tips - newser.com
Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award - The Manila Times
Agilent Technologies (NYSE: A) Debuts Altura Ultra Inert HPLC With 2x Sensitivity - Stock Titan
Detecting price anomalies in Cadrenal Therapeutics Inc. with AITreasury Yields & Fast Gaining Stock Reports - newser.com
What the charts say about Cadrenal Therapeutics Inc. todayWatch List & Daily Stock Trend Watchlist - newser.com
Is Cadrenal Therapeutics Inc. stock attractive for retirement portfolios2025 Breakouts & Breakdowns & Risk Managed Investment Entry Signals - newser.com
Cadrenal Therapeutics Receives Legal Opinion From Blank Rome LLP On ?Validity Of Share Offering - MarketScreener
Cadrenal Therapeutics Announces New Stock Offering Program - TipRanks
Cadrenal Therapeutics IncBlank Rome LLP issued legal opinion on $3,438,062 sharesSEC filing - MarketScreener
[8-K] Cadrenal Therapeutics, Inc. Reports Material Event | CVKD SEC FilingForm 8-K - Stock Titan
Price momentum metrics for Cadrenal Therapeutics Inc. explainedDividend Hike & AI Forecast for Swing Trade Picks - newser.com
Quantitative breakdown of Cadrenal Therapeutics Inc. recent move2025 Major Catalysts & Growth Focused Entry Reports - newser.com
What institutional flow reveals about Cadrenal Therapeutics Inc.Insider Selling & Verified Entry Point Signals - newser.com
Cadrenal Therapeutics Inc (CVKD) 財務データ
収益
当期純利益
現金流量
EPS
Cadrenal Therapeutics Inc (CVKD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Szot Matthew K | Chief Financial Officer |
Oct 24 '25 |
Sale |
13.99 |
1,800 |
25,182 |
11,733 |
| Pham Quang X | CEO and Chairman |
Oct 27 '25 |
Sale |
13.99 |
1,315 |
18,397 |
196,089 |
| Pham Quang X | CEO and Chairman |
Oct 24 '25 |
Sale |
14.03 |
1,129 |
15,840 |
197,404 |
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):